Therefore, the inhibition of ActRIIB signaling has become a novel therapeutic approach in improving obesity and obesity-linked metabolic diseases (Koncarevic et al., 2012). The gene discussed is ACVR2B; the disease is obesity due to melanocortin 4 receptor deficiency.